MINI ABSTRACTWe present our 14-year experience of liver resection for hilar and peripheral cholangiocarcinomas with an analysis of the clinical and pathologic prognostic factors, overall survival and disease-free survival.
ResultsThe survival rates for HCCA and PCCA at one-year were 79% (± 8%) and 67% (± 8%); at three years, 39<'10 (± 10%) and 40% (± 9%); and at five years, 8% (± 7%) and 35% (± 10%), respectively. The disease-free survival rates for HCCA and PCCA were 85% (±1O%) and 77% (±9<'Io) at 1 year; 18% (±11%) and 41% (± 12%) at 3 years; and 18% (±11 %) and 41 % (±12%) at 5 years, respectively. With HCCA, no risk factors were associated with patient survival. For PCCA, multiple tumors (RR=3.5; 95% confidence interval=1.2 to 10.5) and incomplete resection (RR=8.3; 95% confidence interval=2.3 to 29.6) were independently associated with a worse prognosis. For HCCA, there was a trend for lower disease-free survival in female patients (p=O.056; logrank test). For PCCA, tumor size greater than 5 cm was the only factor associated with disease-recurrence (p=0.024; logrank) . Postoperative morbidity and mortality (30 day) were 32% and 14%, respectively for HCCA, and 24% and 3 6% forPCCA.
ConclusionsEven though rare, five year survival by resection can be achieved in both HCCA and PCCA; but new adjuvant treatments are clearly needed.
ABSTRACTBackground. Long term survival achieved after surgical treatment of hilar